Made available in DSpace on 2014-06-11T19:26:04Z (GMT). No. of bitstreams: 0 Previous issue date: 2009-02-09Bitstream added on 2014-06-13T19:53:58Z : No. of bitstreams: 1 rubio_ml_me_sjrp.pdf: 553575 bytes, checksum: e63be6b1c41d36a603fd12ca20a88442 (MD5) / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) / Fundação para o Desenvolvimento da UNESP (FUNDUNESP) / Paramyxoviridae, é um vírus envelopado com tamanho médio de 120 a 300nm, de simetria helicoidal, que apresenta um genoma de RNA fita simples não segmentado de polaridade negativa. Este genoma codifica 11 proteínas, dentre as quais as glicoproteínas de membrana que são responsáveis pela infectividade do vírus. A proteína F, em associação com a proteína G e SH, é responsável pela fusão da membrana viral à célula que será infectada, ou seja, esta proteína proporciona a entrada e instalação do vírus na célula. Conhecer a forma de interação das proteínas da membrana viral com a célula que será infectada é importante para propor um mecanismo de inibição deste processo de infecção viral. Existem evidências que os glicosaminoglicanos são potenciais inibidores da infecção causada por vários vírus. A hipótese é de que este processo de inibição ocorra devido à ligação dos glicosaminoglicanos às proteínas da membrana viral, mais especificamente na proteína G, que apresenta um domínio de ligação para heparina, impedindo desta forma, que o vírus se ligue na célula hospedeira e que inicie o processo de infecção. O objetivo deste trabalho foi verificar a atuação de glicosaminoglicanos como potenciais inibidores da infecção viral. Esta análise foi realizada por meio de experimento de cultivo de células Hep2 na presença dos glicosaminoglicanos heparina e dextrana sulfatada que foram inoculadas com o vírus sincicial respiratório do tipo A (RSVA) e analisados por meio das técnicas de PCR e Imunofluorescência Indireta. Os resultados mostraram que a heparina e a dextrana sulfatada apresentam efeito inibitório da infecção viral em cultivo de células Hep2. / The respiratory sincicial virus (RSV) is part of Pneumovirus genus of the Paramyxoviridae family, is an enveloped virus with average size of 120 to 300nm, helical symmetry, that presents a genome consisting of a single strand, no segmented, RNA negative. This genome codifies for 11 proteins including the membrane glycoproteins which are responsible for the infectivity of the virus. Protein F in association with protein G and SH is responsible for the fusion of the viral membrane with the cell that will be infected, that is, this protein provides the entrance and the virus to settle in the cell. To know the form of interaction of viral membrane proteins with the cell that will be infected is important to propose a mechanism to inhibit of this process of viral infection. Evidences exist that the glycosaminoglycans are potential inhibitors of the infection caused by some viruses. The hypothesis is that this process of inhibition occurs more specifically due to the interation between glycosaminoglycans and the proteins of the viral membrane, more specifically in protein G, that presents a domain of linking for heparin, avoiding the virus to bind to the host cell and initiating the infection process. The aim of this work was to verify the performance of glycosaminoglycans as inhibitors of the viral infection. This analysis was accomplished through experiments of Hep2 cell culture in the presence of these glycosaminoglycans (heparin and dextran sulfate) that was inoculated with the respiratory sincicial virus type A (RSVA) and analyzed through the technique of PCR and Indirect Imunofluorecence. The results had shown that the heparin and the dextran sulfate presented an inhibitory effect of the viral infection in Hep2 cells culture.

Objetivos: Investigar o dano a lipídios, proteínas e ao DNA, níveis de glicosaminoglicanos (GAGs) e as concentrações de interleucina 1-β (IL1-β) em sangue de pacientes com Mucopolissacaridose (MPS) tipo II no diagnóstico e durante a terapia de reposição enzimática (TRE) e correlacioná-los com parâmetros de estresse oxidativo, bem como analisar o efeito in vitro da genisteína sob o dano ao DNA em leucócitos de pacientes com MPS tipo IVA. Métodos: Amostras de sangue e urina de doze pacientes com MPS II no diagnóstico e sob tratamento com TRE, além de controles saudáveis foram utilizados para avaliar: índice de lipoperoxidação e oxidação de proteínas (medida a partir do conteúdo de grupamentos carbonila e SH) em plasma, GAGs urinários, níveis de IL1-β plasmáticos, bem como índice de dano ao DNA em leucócitos através do ensaio cometa, também utilizada para avaliar o dano ao DNA em leucócitos de pacientes com MPS IVA, previamente incubados em diferentes concentrações de genisteína ou em tampão fosfato salino e dimetilsulfóxido. Resultados e Discussão: Foi observada a presença de dano oxidativo a biomoléculas em sangue de pacientes com MPS II, com altos níveis de lipoperoxidação, conteúdo de grupamentos carbonila, dano ao DNA e redução de grupos sulfidrila. Houve redução no dano ao DNA e na lipoperoxidação após TRE, além de aumento de grupamentos sulfidrila, embora a terapia não tenha sido capaz de reverter o dano a carbonila. Nossos resultados sugerem que o aumento dos GAGs induz o dano aos lipídios e ao DNA. A adição in vitro de genisteína (10, 30 e 50 μM) em amostras de sangue de pacientes MPS IVA acarretou em um aumento estatisticamente significativo no índice de dano ao DNA. Conclusões: Estresse oxidativo e inflamação estão envolvidos na fisiopatologia da MPS II. Além disso, a TRE mostrou ter papel protetor contra o dano ao DNA e a lipídios. A genisteína nas doses 10, 30 e 50 μM aumentou in vitro o índice de dano ao DNA em leucócitos de pacientes MPS IVA, demonstrando citotoxicidade. / Objectives: Investigate lipid, protein and DNA damage, glycosaminoglycans (GAGs) levels and the inflammatory marker interleukin 1-β (IL1-β) concentration of mucopolysaccharidosis (MPS) II patients at the moment of diagnosis and during enzyme replacement therapy (ERT), correlate these findings with oxidative stress parameters, as well as investigate the in vitro effect of genistein on DNA injury in leukocytes from MPS IVA patients. Material and Methods: Blood and urine samples from twelve MPS II patients at diagnosis and under ERT and healthy controls were evaluated regarding the parameters: lipid peroxidation index and protein oxidation (carbonyl and SH group contents) in plasma, urinary GAGs, as well as IL-1β in plasma and DNA damage index in leukocytes. Besides, blood samples from MPS IVA patients were incubated with different concentrations of genistein or phosphate buffered saline (PBS) and dimethylsulfoxide (DMSO), and the DNA damage index in leukocytes was evaluated by the comet assay. Results and Discussion: MPS II patients presented oxidative damage to biomolecules with high levels of lipid peroxidation, carbonyl content and DNA damage, as well as a reduction on SH groups. There was a decrease in DNA damage and lipid oxidative injury after ERT, and an increase in SH levels, although this therapy was not able to reverse carbonyl content. The high levels of urinary GAGs in MPS II patients were reduced after ERT and positively correlated with DNA and lipid oxidative injury, suggesting that GAGs accumulation induce lipid peroxidation and DNA damage. MPS IVA patients blood treated in vitro with genistein (10, 30 e 50 μM) had higher DNA damage index when compared to samples treated with PBS buffer and DMSO. Conclusions: Oxidative stress and inflammation process are involved in MPS II pathophysiology, and ERT protects against DNA and lipid injury, probably by reducing GAGs accumulation. Genistein increased in vitro DNA damage in leukocytes from MPS IVA patients, demonstrating cytotoxicity.

Este estudo avaliou a efetividade de uma nova membrana bioabsorvível com propriedades mecânicas e químicas mais adequadas para o uso em tendões. A avaliação foi realizada em coelhos submetidos a reconstrução da porção gastrocnêmia do tendão calcâneo. Foi feita uma avaliação prévia das propriedades mecânicas da membrana com uso de dinamômetro digital que demonstrou capacidade de deformação elástica mínima de 100%. Todos os coelhos foram submetidos a tenotomia e reparo da porção gastrocnêmia do tendão direito, após isso foram randomicamente separados em grupos envelopado com membrana e controle. A extração foi realizada nos seguintes períodos: sete, 14 e 28 dias. A avaliação foi realizada através da macroscopia, histologia, mensuração objetiva do colágeno à luz polarizada pelo image-J®, mensuração de glicosaminoglicanos sulfatados e expressão gênica de proteoglicanos. Na avaliação macroscópica o grupo com membrana apresentou menos aderência e melhor direcionamento das fibras e tecido mais homogêneo em 14 e 28 dias, p=0,02 e 0,03 respectivamente. Na histologia a Classificação de Watkins modificada apresentou as seguintes médias: 14,67±0,42 membrana e 12,67±0,56 sem membrana, p=0,03 em 14 dias, e 19,88±0,83 membrana e 17,25±0,62 sem membrana, p=0,02 em 28 dias. Na mensuração do colágeno as médias dos valores de cinza(mvc) o colágeno tipo III foram de 17,97±1,83 membrana e 12,63±1,07 sem membrana p=0,03 em 14 dias. Para o colágeno tipo I as médias foram de 2,41±0,33mvc membrana e 1,31±0,18mvc sem membrana p=0,01 em 14 dias e 7,30±0,63mvc membrana e 2,92±0,32mvc sem membrana p < 0,0001 em 28 dias. A média dos GAGs foi avaliada em três porções do tendão, proximal, central e distal, em ug/mg de tecido seco. Em sete dias apresentou diferença significativa apenas na porção distal 0,80±0,04 com e 0,38±0,04 sem membrana para condroitin-sulfato em 14 dias não apresentou diferenças entre os grupos. O dermatan-sulfato apresentou diferença estatisticamente significante em 7 dias apenas na porção central 0,42±0,09 com membrana e 1,29±0,67 sem membrana p=0,02. Em 14 dias não foram observadas diferenças entre os grupos. Houve grande variabilidade na expressão gênica no teste das amostras com beta-Actina e GAPDH levando a resultados inconclusivos ou não variação entre os grupos que pode sugerir não variabilidade na expressão gênica dos GAGs no período de 28 dias. Os dados fornecidos por esse trabalho mostram que a envelopagem com a membrana bioabsorvível promoveu aceleração dos processos cicatriciais da porção gastrocnêmia do tendão calcâneo de coelhos / This study assessed the effectiveness of a new absorbable membrane, that presents mechanical and chemical features more suitable to tendons, in rabbit tendons. Before the animal model assessments a mechanical study of the membrane was carried out demonstrating that the minimal capability for elastic deformation of the membrane was more than 100%. All rabbits underwent to tenotomy and reconstruction of the right gastrocnius tendons, thereafter they were randomly divided in tendon wrapped by the membrane and control groups. Extraction was performed in the following periods of time: seven, 14 and 28 days. Assessments used macroscopy, histology, objective collagen assessment by using polarized light and Image-J® program in mean of gray values(mgv), sulphated glycosaminoglycans, genetic expression of proteoglycans. In the macroscopic 14 and 21-day assessments the membrane group presented less adherences p=0.02 and p=0.03 respectively. The modified Watkins classification: 14,67±0,42 membrane and 12,67±0,56 without membrane p=0,03 for 14 days; 19,88±0,83 membrane and 17,25±0,62 without membrane p=0,02 for 28 days. The type III collagen were 17,97±1,83 membrane and 12,63±1,07 without membrane p=0,029 for 14 days. For type I collagen were 2,41±0,33 membrane and 1,31±0,18 without membrane p=0,01 for 14 days and 7,30±0,63 memebrane and 2,92±0,32 without membrane p < 0,0001 for 28 days. The glycosaminoglycans were measured in 3 tendon portions, distal, central and proximal, by using ug/mg of dry tissue. In seven days just the distal part presented statistical differences 0,80±0,04 membrane and 0,38±0,04 without membrane, for 14 days no differences were found for Chondroitin-Sulphate. For Dermatan-Sulphate the central part of the tendon 0,42±0,09 and 1,29±0,67 p=0,02, for 14 days no differences were found. There was high variability for beta-actin and GAPDH for the samples in 28 days with inconclusive results that may mean no variability in gene expression of GAGs at this time period. Results as mentioned above demonstrated that the wrapped tendons by the new membrane presented acceleration in the healing processes for gastrocnemius tendons of New Zealand Rabbits

Objetivos: Investigar o dano a lipídios, proteínas e ao DNA, níveis de glicosaminoglicanos (GAGs) e as concentrações de interleucina 1-β (IL1-β) em sangue de pacientes com Mucopolissacaridose (MPS) tipo II no diagnóstico e durante a terapia de reposição enzimática (TRE) e correlacioná-los com parâmetros de estresse oxidativo, bem como analisar o efeito in vitro da genisteína sob o dano ao DNA em leucócitos de pacientes com MPS tipo IVA. Métodos: Amostras de sangue e urina de doze pacientes com MPS II no diagnóstico e sob tratamento com TRE, além de controles saudáveis foram utilizados para avaliar: índice de lipoperoxidação e oxidação de proteínas (medida a partir do conteúdo de grupamentos carbonila e SH) em plasma, GAGs urinários, níveis de IL1-β plasmáticos, bem como índice de dano ao DNA em leucócitos através do ensaio cometa, também utilizada para avaliar o dano ao DNA em leucócitos de pacientes com MPS IVA, previamente incubados em diferentes concentrações de genisteína ou em tampão fosfato salino e dimetilsulfóxido. Resultados e Discussão: Foi observada a presença de dano oxidativo a biomoléculas em sangue de pacientes com MPS II, com altos níveis de lipoperoxidação, conteúdo de grupamentos carbonila, dano ao DNA e redução de grupos sulfidrila. Houve redução no dano ao DNA e na lipoperoxidação após TRE, além de aumento de grupamentos sulfidrila, embora a terapia não tenha sido capaz de reverter o dano a carbonila. Nossos resultados sugerem que o aumento dos GAGs induz o dano aos lipídios e ao DNA. A adição in vitro de genisteína (10, 30 e 50 μM) em amostras de sangue de pacientes MPS IVA acarretou em um aumento estatisticamente significativo no índice de dano ao DNA. Conclusões: Estresse oxidativo e inflamação estão envolvidos na fisiopatologia da MPS II. Além disso, a TRE mostrou ter papel protetor contra o dano ao DNA e a lipídios. A genisteína nas doses 10, 30 e 50 μM aumentou in vitro o índice de dano ao DNA em leucócitos de pacientes MPS IVA, demonstrando citotoxicidade. / Objectives: Investigate lipid, protein and DNA damage, glycosaminoglycans (GAGs) levels and the inflammatory marker interleukin 1-β (IL1-β) concentration of mucopolysaccharidosis (MPS) II patients at the moment of diagnosis and during enzyme replacement therapy (ERT), correlate these findings with oxidative stress parameters, as well as investigate the in vitro effect of genistein on DNA injury in leukocytes from MPS IVA patients. Material and Methods: Blood and urine samples from twelve MPS II patients at diagnosis and under ERT and healthy controls were evaluated regarding the parameters: lipid peroxidation index and protein oxidation (carbonyl and SH group contents) in plasma, urinary GAGs, as well as IL-1β in plasma and DNA damage index in leukocytes. Besides, blood samples from MPS IVA patients were incubated with different concentrations of genistein or phosphate buffered saline (PBS) and dimethylsulfoxide (DMSO), and the DNA damage index in leukocytes was evaluated by the comet assay. Results and Discussion: MPS II patients presented oxidative damage to biomolecules with high levels of lipid peroxidation, carbonyl content and DNA damage, as well as a reduction on SH groups. There was a decrease in DNA damage and lipid oxidative injury after ERT, and an increase in SH levels, although this therapy was not able to reverse carbonyl content. The high levels of urinary GAGs in MPS II patients were reduced after ERT and positively correlated with DNA and lipid oxidative injury, suggesting that GAGs accumulation induce lipid peroxidation and DNA damage. MPS IVA patients blood treated in vitro with genistein (10, 30 e 50 μM) had higher DNA damage index when compared to samples treated with PBS buffer and DMSO. Conclusions: Oxidative stress and inflammation process are involved in MPS II pathophysiology, and ERT protects against DNA and lipid injury, probably by reducing GAGs accumulation. Genistein increased in vitro DNA damage in leukocytes from MPS IVA patients, demonstrating cytotoxicity.

Les thérapies ciblées constituent une révolution médicale dans le traitement du cancer. Dans ce contexte, le pseudopeptide multivalent N6L, qui cible spécifiquement les cellules tumorales et induit leur mort, apparaît comme une molécule prometteuse. Le N6L cible en effet deux nucléoprotéines surexprimées à la surface des cellules cancéreuses qui sont la nucléoline et la nucléophosmine. L'étude du mécanisme d'action anti-métastatique du N6L, dans lequel l'implication du TIMP-3 a été soulignée, a permis d'identifier une nouvelle cible : les glycosaminoglycanes sulfatés (GAG).Dans le but de développer une approche multimodale pour le diagnostic et le traitement du cancer du sein, le N6L a été greffé à la surface de nanoparticules magnétiques (NPM-N6L). La propriété de ciblage tumorale des NPM-N6L a été démontrée in vitro et in vivo. Leur cible tumorale majeure fut les GAG.Par ailleurs, l'activité anti-tumorale du N6L dans le traitement du cancer de la prostate à différents stades de la maladie a été démontrée in vitro et in vivo. La cible tumorale mise en jeu fut la nucléophosmine. En outre, ce potentiel anti-tumoral implique une diminution de l'activité du récepteur aux androgènes et probablement une voie de signalisation impliquant une interaction entre la nucléophosmine phosphorylée et le récepteur aux androgènes. / Targeted therapies constitute a revolution in the medical treatment of cancer. In this context, the multivalent pseudopeptide N6L that specifically target tumor cells and induces their death seems a promising molecule. The N6L targets two nucleoproteins that are overexpressed on the surface of cancer cells: nucleolin and nucleophosmin. The study of the N6L anti-metastatic mechanism of action in which TIMP-3 was involved, has identified a new target: sulfated glycosaminoglycans (GAG).In order to develop a multimodal approach for diagnosis and treatment of breast cancer, the N6L was grafted to the surface of magnetic nanoparticles (MNP-N6L). Tumor targeting properties of MNP-N6L was demonstrated in vitro and in vivo. Their major tumor target was GAG.Furthermore, the N6L anti-tumor activity in the treatment of prostate cancer at different stages of the disease was demonstrated in vitro and in vivo. The target involved in this activity was nucleophosmin. Furthermore, this anti-tumor potential implies a decrease in the activity of the androgen receptor and probably a signaling pathway involving an interaction between phosphorylated nucleophosmin and the androgen receptor.

Content: A comprehensive analysis of the molecular and structural components of deer skin and cow hide was undertaken. These skins known to be strong, however they derive their strength from different combinations of molecular and structural properties. Firstly, the physical properties of deer skin and cow hide including the tensile strength, tear strength and denaturation temperature were measured. Secondly, the structure of the collagen fibrils and glycosaminoglycans was investigated using transmission electron microscopy (TEM), and small angle X-ray scattering (SAXS). Finally, the chemical composition of deer skin and cow hide such as amino acids, crosslinks and glycosaminoglycans were analysed. Our results showed that physical properties of deer skin and cow hide are derived from different combinations of several chemical components resulting in different architecture. It was found that the large and “wavy” collagen fibres in deer skin made up of collagen fibrils with small diameters. Additionally, deer skin fibrils appeared to be linked by regular arrays of filaments of large glycosaminoglycans that are distributed uniformly. Deer skin contained higher proportion of trivalent collagen crosslinks. In contrast, the collagen fibrils in cow hide were large, contained a diverse glycosaminoglycan distribution and a higher proportion of tetravalent collagen crosslinks, resulting in straight collagen fibres. This study suggests that although deer skin and cow hide are both strong, they have different structural and molecular features. Take-Away: Deer skin and cow hide have different structural and molecular make up which are reflected in their physical properties particularly strength. Glycosaminoglycans are important for the organisation of collagen fibrils in deer skin and cow hide. Deer skin and cow hide contain different ratios of collagen natural crosslinks which are essential collagen stability.

Glycosaminoglycans (GAGs) are linear polysaccharides, built of periodically occurring disaccharide units. GAGs are ubiquitous in the extracellular matrix (ECM), where they exhibit multifarious biological activities. This diversity arises from - among others - their ability to interact with and regulate a large number of proteins, such as cytokines, chemokines, and growth factors. As of the huge variety in their chemical configuration, GAGs are further sub-classified into different types (heparin, for instance, is one of these sub-classes). Hence, GAGs are a diverse class of molecules, which surely contributes to the broadness of their spectrum of biological functions. Through varying arrangements of sulfate groups and different types of saccharide units, individual GAG molecules can establish specific atomic contacts to proteins. One of the best-studied examples is antithrombin-heparin, whose biologically relevant interaction requires a specific pentasaccharide sequence. It is valid to assume, however, that various proteins are yet to be discovered whose biological functions are in some way affected by GAGs. In other cases, and this is true for the cytokine interleukin-10 (IL-10), there are already experimental indications for a biologically relevant protein-GAG interaction, but the details are still obscure and the fundamental molecular interaction mechanism has still not been clarified. IL-10 has been shown to bind GAGs. So far, however, no structural detail about IL-10-GAG interaction is known. Function-wise, IL-10 is mainly considered to be immunosuppressive and therefore anti-inflammatory, but it in fact has the pleiotropic ability to influence the immune system in both directions, i.e. it constitutes a complex regulation system on its own. Therefore, the role of GAGs in this system is potentially substantial, but is yet to be clarified. In vitro experiments have yielded indications for GAGs being able to modulate IL-10\'s biological function, and obviously IL-10 and GAGs are simultaneously present in the ECM. This gives rise to the assumption that IL-10-GAG interaction is of biological significance, and that understanding the impact of GAGs on IL-10 biology is important - from the basic research point of view, but also for the development of therapies, potentially involving artificially designed ECMs. A promising approach for obtaining knowledge about the nature of IL-10-GAG interaction is its investigation on the structural level, i.e. the identification and characterization of the molecular interaction mechanisms that govern the IL-10-GAG system. In this PhD project it was my goal to reveal structural and molecular details about IL-10-GAG interaction with theoretical and computational means, and with the help of experiments performed by collaborators in the framework of the Collaborative Research Centre DFG Transregio 67. For achieving this, I developed three methods for the in silico investigation of protein-GAG systems in general and subsequently applied them to the IL-10-GAG system. Parts of that work have been published in scientific journals, as outlined further below. I proposed and validated a systematic approach for predicting GAG binding regions on a given protein, based on the numerical simulation and analysis of its Coulomb potential. One advantage of this method is its intrinsic ability to provide clues about the reliability of the resulting prediction. Application of this approach to IL-10 lead to the observation that its Coulomb attraction for GAGs is significantly weaker than in case of exemplary protein-GAG systems (such as FGF2-heparin). Still, a distinct IL-10-GAG binding region centered on the residues R102, R104, R106, R107 of the human IL-10 sequence was identified. This region can be assumed to play a major role in IL-10-GAG interaction, as described in chapter 3. Molecular docking methods are used to generate binding mode predictions for a given receptor-ligand system. In chapter 4, I clarify the importance of data clustering as an essential step for post-processing docking results and present a clustering methodology optimized for GAG molecules. It allows for a reproducible analysis, enabling systematic comparisons among different docking studies. The approach has become standard procedure in our research group. It has been applied in a variety of studies, and served as an essential tool for studying IL-10-GAG interaction, as described in chapter 3. Motivated by the shortcomings of classical docking approaches, especially with respect to protein-GAG systems, I worked on the development of a molecular dynamics-based docking method with less radical approximations than usually applied in classical docking. The goal was to make the computational model properly account for the special physical properties of GAGs, and to include the effects of receptor flexibility and solvation. The methodology was named Dynamic Molecular Docking (DMD) and published in the Journal of Chemical Information and Modeling-together with a validation study. The subsequent application of DMD in a variety of studies required enormous amounts of computational resources. For tackling this challenge, I established a graphics processing unit-based high-performance computing environment in our research group and developed a software framework for reliably performing DMD studies on this hardware, as well as on other computing resources of the TU Dresden. The investigation of the IL-10-GAG system via DMD was focused on the IL-10-GAG binding region predicted earlier, and made heavy usage of the optimized clustering approach named above. An important result of this endeavor is that IL-10's amino acid residue R107 significantly stands out compared to all other residues and supposedly plays a particularly important role in IL-10-GAG recognition. The collaboration with the NMR laboratory of Prof. Daniel Huster at the Universität Leipzig was fruitful: I post-processed nuclear Overhauser effect data and obtained heparin structure models, which revealed that IL-10-heparin interaction has a measurable impact on the backbone structure of the heparin molecule. These results were published in Glycobiology. In chapter 8, I propose two different scenarios about how GAG-binding to IL-10 might affect its biological function, based on the findings made in this thesis project. In conclusion, a set of methods has been developed, all of which are generically applicable for the investigation of protein-GAG systems. Regarding the IL-10-GAG system, valuable structural insights for increasing the understanding about its molecular mechanisms were derived. These observations pave the way towards unraveling GAG-mediated bioactivity of IL-10, which may then be specifically exploited, for instance in artificial ECMs for improved wound healing.

Host cell binding is an essential step in colonization by many bacterial pathogens, and the Lyme disease agent, Borrelia burgdorferi, which colonizes multiple tissues, is capable of attachment to diverse cell types. Glycosaminoglycans (GAGs) are ubiquitously expressed on mammalian cells and are recognized by multiple B. burgdorferi surface proteins. We previously showed that B. burgdorferi strains differ in the particular spectrum of GAGs that they recognize, leading to differences in the cultured mammalian cell types that they efficiently bind. The molecular basis of these binding specificities remains undefined, due to the difficulty of analyzing multiple, potentially redundant cell attachment pathways and to the paucity of genetic tools for this pathogen. Complementation of a high-passage non-adherent B. burgdorferi strain reveals that the expression of DbpA, DbpB, or BBK32, is sufficient to confer efficient spirochete attachment to 293 epithelial cells. Epithelial cell attachment by DbpA and B was mediated by dermatan sulfate, while BBK32 recognized dermatan and heparan sulfate. The GAG binding properties of bacteria expressing DbpB or DbpA were distinguishable in that DbpB, but not DbpA, promoted spirochetal attachment to C6 glial cells. Furthermore, DbpA alleles from diverse Lyme disease spirochetes exhibit allelic variation with respect to binding decorin, dermatan sulfate, and epithelial cells. Targeted disruption of bbk32 resulted in decreased spirochete binding to fibronectin, GAGs, and mammalian cells. Thus, DbpA, DbpB, and BBK32 may play central but distinct roles in cell type-specific binding by Lyme disease spirochetes. This study illustrates that transformation of high-passage B. burgdorferi strains and targeted gene disruption provide a comprehensive genetic approach to analyze virulence-associated phenotypes conferred by multiple bacterial factors.

Die aufgrund des demografischen Wandels steigende Zahl an Patienten mit Knochendefekten, chronischen Wunden und einhergehender Multimorbidität stellt ein großes klinisches und sozioökonomisches Problem dar. Derzeitige etablierte Verfahren zur Behandlung von Knochen- und Hautdefekten weisen zahlreiche Nachteile auf, weshalb die Erforschung innovativer Methoden notwendig ist. Ein vielversprechender Ansatz zur Verbesserung der Wundheilungskapazität ist die Funktionalisierung von Biomaterialien mit Komponenten der extrazellulären Matrix (ECM), die eine Rolle bei der Geweberegeneration spielen. Glykosaminoglykane (GAGs) sind wichtige ECM-Komponenten, von denen bekannt ist, dass sie mit Mediatorproteinen interagieren, wodurch sie deren biologische Aktivität und damit zelluläre Prozesse beeinflussen. Native GAGs, wie Heparansulfat, sind jedoch aufgrund ihrer eingeschränkten Verfügbarkeit, Charge-zu-Charge-Variabilität und ihrer quellenabhängigen biologischen Aktivität nur begrenzt für biomedizinische Anwendungen geeignet. Daher sind chemisch modifizierte Hyaluronsäure (HA)- und Chondroitinsulfat (CS)-Derivate mit definierten Eigenschaften bezüglich des Kohlenhydratrückgrats, sowie des Sulfatierungsgrades und -musters besonders geeignet, um ihre Struktur-Eigenschaftsbeziehung in der Interaktion mit heilungsrelevanten Mediatorproteinen und Zellen zu untersuchen. Ziel der vorliegenden Arbeit war die Untersuchung der zugrundeliegenden molekularen Mechanismen, mit denen GAGs zelluläre Prozesse direkt oder indirekt durch Bindung von Wachstumsfaktoren beeinflussen. Hierbei sollte vor allem gezeigt werden, wie Kohlenhydratrückgrat, Sulfatierungsgrad und -muster der GAG-Derivate die Interaktion und damit die biologische Aktivität des transformierenden Wachstumsfaktors (TGF)-β1, sowie der angiogenen Mediatoren vaskulärer endothelialer Wachstumsfaktor (VEGF)165 und basischer Fibroblasten-Wachstumsfaktor (bFGF) beeinflussen. In vorangegangen Studien wurde gezeigt, dass sulfatierte HA- (sHA) und CS-Derivate stark mit Wachstumsfaktoren, wie den knochenmorphogenetischen Proteinen (BMP)-2/-4 und TGF-β1 wechselwirken. Letzterer wies eine beeinträchtigte Bioaktivität in Gegenwart von hochsulfatierter HA (sHA3) auf. Der zugrundeliegende Mechanismus wurde bisher nicht vollständig aufgeklärt und daher in dieser Arbeit untersucht. Oberflächenplasmonresonanz (SPR)-Untersuchungen mit allen Komponenten des TGF-β1:Rezeptor-Komplexes in Anwesenheit von GAGs zeigten, dass die Vorinkubation von TGF-β1 mit sHA-Derivaten die Bindung von TGF-β1, insbesondere an TGF-β Rezeptor (TβR)-I, aber auch an TβR-II, blockierte. In sequentiellen SPR-Experimenten, welche die in vivo-TGF-β1:Rezeptor-Komplexbildung genauer nachahmen, war jedoch die Rekrutierung von TβR-I zum TβR-II/TGF-β1-Komplex signifikant stärker, wenn der Komplex sHA3 enthielt. GAGs üben somit einen dualen Blockierungsmechanismus auf die TGF-β1:Rezeptor-Komplexbildung aus, wobei die Effekte stark von der Reihenfolge der Bindungsereignisse abhängen. Die hier erstmals untersuchte Bioaktivität von TGF-β1 in Verbindung mit sHA auf Rezeptorebene zeigte eine Abnahme der Phosphorylierung für TβR-I und das TβR-I-regulierte Effektorprotein Smad2 in Gegenwart von sHA3, was auf die Bildung eines inaktiven Signalkomplexes hindeutet. Ebenfalls analysiert wurde die Struktur-Eigenschaftsbeziehung von HA- und CS-Derivaten in ihrer Wechselwirkung mit den wichtigsten angiogenen Wachstumsfaktoren: VEGF165 und bFGF. Ziel war es strukturelle Eigenschaften zu identifizieren, die zu einer Interaktion beitragen und die biologischen Konsequenzen von Wachstumsfaktor/GAG-Interaktion zu ermitteln. Beide Wachstumsfaktoren zeigten eine sulfatierungsabhängige Wechselwirkung mit GAG-Derivaten in der SPR-Bindungsanalyse. Anders als bFGF zeigte VEGF165 außerdem eine klare Präferenz für sHA im Vergleich zu CS-Derivaten, was darauf hindeutet, dass die Wechselwirkung mit diesem Wachstumsfaktor nicht nur vom Sulfatierungsgrad, sondern auch vom Kohlenhydrat-Rückgrat des GAGs beeinflusst wird. sHA-Tetramere waren ausreichend, um mit VEGF165 und bFGF in SPR-Messungen zu interagieren und zeigten, dass die Position der Sulfatierung eine wichtige Rolle bei der Interaktion mit beiden angiogenen Wachstumsfaktoren zu spielen scheint, da die Bindungsstärke des sHA-Tetrasaccharids ohne C6-Sulfatierung des N-Acetylglucosamins (GlcNAc) im Vergleich zu einem ausschließlich an der C6-Position sulfatiertem Derivat geringer war. Interessanterweise war die Bindung von tetramerer persulfatierter HA (psHA) im Vergleich zu einem psHA-Hexamer stärker, was darauf hinweist, dass das Tetrasaccharid in der Lage ist, mit zusätzlichen GAG-Bindungsstellen von VEGF165 und bFGF zu interagieren. Die Bindung von VEGF165 und bFGF an ihre jeweiligen Rezeptoren VEGF Rezeptor (VEGFR)-2 und FGF Rezeptor (FGFR) 1 war vermindert, wenn die Wachstumsfaktoren in SPR-Studien mit sulfatierten GAGs vorinkubiert wurden. Auch hier wurde für VEGF165 ein Einfluss des Kohlenhydratrückgrats nachgewiesen, da die Bindung des Wachstumsfaktors an VEGFR-2 durch sHA-Derivate stärker gehemmt wurde als durch CS-Derivate mit vergleichbarem Sulfatierungsgrad. Auch auf die bFGF/FGFR1IIIc-Interaktion hatte die Sulfatierung der C6-Position des GlcNAc von sHA1 einen stärkeren Einfluss als die C4-Sulfatierung des GlcNAc von CS. Im Gegensatz dazu war die Blockierungskapazität von sCS3 und sHA3 jedoch ähnlich. Dies deutet auf einen geringen Einfluss des Kohlenhydratrückgrats, jedoch auf einen großen Einfluss des gesamten Sulfatierungsgrades der GAG-Derivate auf die bFGF-Wechselwirkung mit FGFR1IIIc hin. Tetramere GAGs waren ebenfalls ausreichend, um die VEGF165- und bFGF-Rezeptorbindung zu stören. Mit zunehmendem Sulfatierungsgrad und Länge des Derivats wurde der Blockierungseffekt verstärkt. Die Interaktion von VEGF165 mit sHA3 und die anschließende Blockierung der VEGFR-2-Bindung führte zu einer verminderten Phosphorylierung von VEGFR-2. In einem 3D in vitro-Angiogenese-Assay zeigte sich darüber hinaus eine verminderte VEGF165- bzw. bFGF-vermittelte Sprossung von Endothelzell-Sphäroiden durch hochsulfatierte GAGs. Die Angiogenese wurde jedoch nicht vollständig inhibiert. Interessanterweise induzierten GAG-Derivate unabhängig von den untersuchten angiogenen Wachstumsfaktoren die Sprossung von Endothelzell-Sphäroiden. Es konnte gezeigt werden, dass VEGFR-2 nicht an der proangiogenen Wirkung von sulfatierten GAGs beteiligt ist, während die Blockierung von FGFR1 die proangiogene Wirkung von sCS3 und sHA3 hemmt. GAG-Derivate könnten FGFR1 direkt aktivieren, da in SPR-Experimenten gezeigt wurde, dass sie an den Rezeptor binden. Andererseits könnte der beobachtete Effekt auch auf eine erleichterte Rezeptordimerisierung mit einer anschließenden verstärkten Ligandenbindung oder die Wechselwirkung mit intrazellulären Targets nach GAG-Internalisierung zurückzuführen sein. Dies muss in weiteren Experimenten geklärt werden. Die Ergebnisse weisen auf die Wichtigkeit der Reihenfolge der Bindungsereignisse hin, da die Bindung von GAG-Derivaten an Wachstumsfaktoren, Rezeptoren oder beide Komponenten zu unterschiedlichen zellulären Konsequenzen hinsichtlich der Signalgebung führt. In der vorliegenden Arbeit wurde gezeigt, dass GAG-Derivate unterschiedliche molekulare Mechanismen nutzen, um zelluläre Prozesse direkt oder indirekt über die Bindung von Wachstumsfaktoren zu modulieren und tragen zu einem tieferen Verständnis ihrer Wirkungsweise bei. Dies könnte wiederum eine Abstimmung der Biomaterial-zusammensetzung auf patientenspezifische Bedürfnisse ermöglichen. GAG-haltige Bio-materialien sind vielversprechend für eine Verminderung TGF-β1-gesteuerter lokaler Hautfibrose, da sie die Bioaktivität von TGF-β1 reduzieren. In Bezug auf die inhibitorischen Effekte auf die VEGF165- und bFGF-Signaltransduktion könnten GAGs mit übermäßiger Angiogenese, die bei rheumatoider Arthritis und diabetischer Retinopathie auftritt, interferieren. Ob diese in vitro-Ergebnisse zur Steuerung der biologischen Aktivität von TGF-β1, VEGF165 und bFGF oder zur direkten Stimulation der Angiogenese unabhängig von Wachstumsfaktoren genutzt werden können, muss in vivo validiert werden. / Age-related pathologies, like chronic wounds and impaired fracture healing are a consequence of a longer life expectancy in our aging population and are associated with considerable clinical and socioeconomic burdens. To improve the wound healing capacity of patients, the development of new adaptive biomaterials to selectively control and promote bone and skin regeneration is essential. A promising approach for the design of such biomaterials incorporates elements of the extracellular matrix (ECM) that play a role in tissue regeneration. Glycosaminoglycans (GAGs) are major ECM components known to interact with important mediator proteins, thereby influencing their biological activity and subsequently cellular processes. However, native GAGs like heparan sulfate have a limited utility for biomedical applications due to their restricted availability, batch-to-batch variability and source-dependent biological activity. For this reason, chemically modified hyaluronan (HA) and chondroitin sulfate (CS) derivatives with defined properties regarding the carbohydrate backbone, the degree of sulfation and the sulfation pattern are preferable for studying their structure-function relationship in the interaction with mediator proteins and cells relevant to healing processes. The aim of the present study was to investigate how GAGs influence cellular processes - directly or indirectly by binding growth factors – and particularly how the sugar backbone as well as the sulfation degree and pattern of GAG derivatives influence the interaction and thus the biological activity of transforming growth factor (TGF)-β1, and the angiogenic mediators vascular endothelial growth factor (VEGF)165 and basic fibroblast growth factor (bFGF). Sulfated HA (sHA) and CS derivatives were reported to strongly interact with growth factors like bone morphogenetic proteins (BMP)-2/-4 and transforming growth factor (TGF)-β1. The bioactivity of the latter was impaired in the presence of highly sulfated HA (sHA3), the underlying mechanism of which is so far not fully elucidated. In the present thesis the interaction of all components of the TGF-β1:receptor complex with sHA was examined by surface plasmon resonance (SPR), showing that pre-incubation of TGF-β1 with sHA derivatives blocked the binding of TGF-β1 in particular to TGF-β receptor (TβR)-I, but also to TβR-II. In sequential SPR experiments that mimicked the in vivo TGF-β1:receptor complex formation more closely, however, recruitment of TβR-I to the TβR-II/TGF-β1 complex was significantly stronger if the complex contained sHA3. GAGs thus exert a dual blocking effect on TGF-β1:receptor complex formation, with the effects strongly depending on the order of binding events. The bioactivity of TGF-β1 in conjunction with sHA at the receptor level, which was investigated here for the first time, showed a decrease of phosphorylation for TβR-I and the TβR-I-regulated effector protein Smad2 in the presence of sHA3, indicating of the formation of an inactive signaling complex. Also analyzed was the structure-function relationship of HA and CS derivatives in their interaction with the most important angiogenic growth factors, namely vascular endothelial growth factor (VEGF)165 and basic fibroblast growth factor (bFGF). The aim was both to identify structural properties that contribute to an interaction and to determine the biological consequences of growth factor/GAG interaction. Both growth factors showed a sulfation-dependent interaction with GAG derivatives in SPR binding analysis. Unlike bFGF, VEGF165 also showed a clear preference for sHA compared to CS derivatives, indicating that the interaction with this growth factor is not only impacted by the degree of sulfation but also by the carbohydrate backbone of the GAG. sHA tetramers were sufficient to interact with VEGF165 and bFGF in SPR measurements. The position of sulfation appears to play an important role in the interaction with both angiogenic growth factors, as the binding strength of the sHA tetrasaccharide with no C6-sulfation of the N-acetylglucosamine (GlcNAc) was lower compared to a derivative exclusively sulfated at the C6 position. Interestingly, binding of tetrameric persulfated HA (psHA) was stronger compared to hexameric psHA, indicating that the tetrasaccharide is able to bind to additional regions of VEGF165 and bFGF. Binding of VEGF165 and bFGF to their respective receptors VEGF receptor (VEGFR)-2 and FGF receptor (FGFR) 1 decreased if the growth factors were pre-incubated with sulfated GAGs in SPR studies. For VEGF165, an influence of the carbohydrate backbone was visible again, since the inhibition of growth factor binding to VEGFR-2 by sHA derivatives was stronger than for CS derivatives with comparable degree of sulfation. For bFGF/FGFR1IIIc interaction, sulfation of the C6 position in GlcNAc of low-sulfated sHA had a stronger impact compared to the C4 sulfation in GlcNAc of CS, while blocking capacity of sCS3 and sHA3 was similar. This suggests a minor influence of the carbohydrate backbone on bFGF interaction with FGFR1IIIc in the presence of GAG derivatives, but a major influence of the overall degree of sulfation. Tetrameric GAGs were already sufficient to interfere with VEGF165 and bFGF receptor binding, but the blocking effect was enhanced with increasing sulfation and chain length of the derivative. The interaction of VEGF165 with sHA3 and the subsequent blocking of VEGFR-2 binding led to an impaired phosphorylation of VEGFR-2. Furthermore, the induction of endothelial cell spheroid sprouting mediated via VEGF165 or bFGF was diminished by high sulfated GAGs as displayed in a 3D in vitro angiogenesis assay. However, angiogenesis was not completely abolished. Interestingly, GAG derivatives induced the sprouting of endothelial cell spheroids independent of the studied angiogenic growth factors. It could be shown that VEGFR-2 is not involved in the pro-angiogenic action of sulfated GAGs, while FGFR1 appears to play a role as blocking it inhibited the pro-angiogenic effect of sCS3 and sHA3. GAG derivatives might directly activate FGFR1 as they bound to the receptor in SPR experiments, but the observed effect might also be due to facilitated receptor dimerization with a subsequent enhanced ligand binding, or to an interaction with intracellular targets after GAG internalization; this needs to be clarified in further experiments. Findings point to the importance of the order of binding events, as binding of GAG derivatives to growth factors, receptors or both leads to different cellular outcomes regarding signaling. Results of the present thesis show that GAG derivatives employ different molecular mechanisms to modulate cellular processes – both directly or indirectly via growth factor binding - and contribute to a deeper understanding of their mode of action, which might allow to tune the biomaterial composition to patient-specific needs. GAG-containing biomaterials are promising candidates to interfere with TGF-β1-driven local skin fibrosis, as they reduce the bioactivity of TGF-β1. Concerning the inhibitory effects on VEGF165 and bFGF signaling, an application of GAGs to interfere with the excessive angiogenesis, occurring in rheumatoid arthritis and diabetic retinopathy could be of interest. Whether these in vitro findings can be used to control the biological activity of TGF-β1, VEGF165 and bFGF or to directly stimulate angiogenesis independent of growth factors needs to be validated in vivo.

The present study analyzes the capacity of collagen (coll)/sulfated glycosaminoglycan (sGAG)-based surface coatings containing bioactive glass nanoparticles (BGN) in promoting the osteogenic differentiation of human mesenchymal stroma cells (hMSC). Physicochemical characteristics of these coatings and their effects on proliferation and osteogenic differentiation of hMSC were investigated. BGN were stably incorporated into the artificial extracellular matrices (aECM). Oscillatory rheology showed predominantly elastic, gel-like properties of the coatings. The complex viscosity increased depending on the GAG component and was further elevated by adding BGN. BGN-containing aECM showed a release of silicon ions as well as an uptake of calcium ions. hMSC were able to proliferate on coll and coll/sGAG coatings, while cellular growth was delayed on aECM containing BGN. However, a stimulating effect of BGN on ALP activity and calcium deposition was shown. Furthermore, a synergistic effect of sGAG and BGN was found for some donors. Our findings demonstrated the promising potential of aECM and BGN combinations in promoting bone regeneration. Still, future work is required to further optimize the BGN/aECM combination for increasing its combined osteogenic effect.